UNAIDS: Global AIDS Response Progress Reporting. 2015. http://www.unaids.org/sites/default/files/sub_landing/2015_GARPR_reporting_overview.pdf. Accessed on; 07/10/2015.
Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S122–129.
Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, Caceres C, Cunningham WE. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–62.
Justman J, Goldberg A, Reed J, Bock N, Njeuhmeli E, Goldzier Thomas A. Adult male circumcision: reflections on successes and challenges. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S140–143.
Weaver J, Newman PA, Williams CC, Massaquoi N, Brown M. “Sisters, Mothers, Daughters and Aunties”: HIV vaccine acceptability among African, Caribbean and other Black women in Toronto. Can J Public Health. 2013;104(5):e413–417.
Dong Y, Shen X, Guo R, Liu B, Zhu L, Wang J, Zhang L, Sun J, Zhang X, Xu J. Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China. PLoS One. 2014;9(11):e111321.
Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med. 2011;3(79):79ps13.
Johnston MI, Fauci AS. HIV vaccine development--improving on natural immunity. N Engl J Med. 2011;365(10):873–5.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.
O’Connell JM, Hogg RS, Chan K, Strathdee SA, McLean N, Martindale SL, Willoughby B, Remis R. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr. 2002;31(5):521–8.
Karim QA, Baxter C. Microbicides for the prevention of sexually transmitted HIV infection. Expert Rev Anti-Infect Ther. 2013;11(1):13–23.
Karim QA, Baxter C, Karim SA. Topical microbicides--what’s new? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S144–149.
Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials. 2011;12:67.
Venables E, Stadler J. ‘The study has taught me to be supportive of her’: empowering women and involving men in microbicide research. Cult Health Sex. 2012;14(2):181–94.
Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, et al. Continued follow-Up of phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated Men. PLoS ONE. 2015;10(9):e0137666.
Koblin BA, Avrett S, Taylor PE, Stevens CE. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(2):165–71.
Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, et al. Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav. 2013;17(2):760–72.
Koblin BA, Heagerty P, Sheon A, Buchbinder S, Celum C, Douglas JM, Gross M, Marmor M, Mayer K, Metzger D, et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12(7):785–93.
Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S, Walker BD. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis. 1996;173(2):476–9.
Jenkins RA, Torugsa K, Markowitz LE, Mason CJ, Jamroentana V, Brown AE, Nitayaphan S. Willingness to participate in HIV-1 vaccine trials among young Thai men. Sex Transm Infect. 2000;76(5):386–92.
McGrath JW, George K, Svilar G, Ihler E, Mafigiri D, Kabugo M, Mugisha E. Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. J Acquir Immune Defic Syndr. 2001;27(4):381–8.
Dhalla S. An update on human immunodeficiency virus vaccine preparedness studies. J Med Microbiol. 2015;64(7):731–8.
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507–15.
Otwombe KN, Sikkema KJ, Dietrich J, de Bruyn G, van der Watt M, Gray GE. Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr. 2011;58(2):211–8.
Ruzagira E, Wandiembe S, Bufumbo L, Levin J, Price MA, Grosskurth H, Kamali A. Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Trop Med Int Health. 2009;14(2):196–203.
Saag MS. Preventing HIV in women--still trying to find their VOICE. N Engl J Med. 2015;372(6):564–6.
Cohen MS, Baden LR. Preexposure prophylaxis for HIV--where do we go from here? N Engl J Med. 2012;367(5):459–61.
Larntz K. Small-sample comparisons of exact levels for chi-squared goodness-of-fit statistics. J Am Stat Assoc. 1978;73(362):253–63.
Earl A, Albarracin D, Durantini MR, Gunnoe JB, Leeper J, Levitt JH. Participation in counseling programs: high-risk participants are reluctant to accept HIV-prevention counseling. J Consult Clin Psychol. 2009;77(4):668–79.
Asiki G, Abaasa A, Ruzagira E, Kibengo F, Bahemuka U, Mulondo J, Seeley J, Bekker LG, Delany S, Kaleebu P, et al. Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine. 2013;31(44):5055–61.
Kiwanuka N, Ssetaala A, Mpendo J, Wambuzi M, Nanvubya A, Sigirenda S, Nalutaaya A, Kato P, Nielsen L, Kaleebu P, et al. High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda. J Int AIDS Soc. 2013;16:18621.
Stern E, Rau A, Cooper D. Sexual and reproductive health perceptions and practices as revealed in the sexual history narratives of South African men living in a time of HIV/AIDS. SAHARA J. 2014;11:233–44.
van der Hoeven M, Kruger A, Greeff M. Differences in health care seeking behaviour between rural and urban communities in South Africa. Int J Equity Health. 2012;11:31.
Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36(1):604–12.
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, et al. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906. J Acquir Immune Defic Syndr. 2013;63(2):239–44.
Kranzer K, Govindasamy D, van Schaik N, Thebus E, Davies N, Zimmermann M, Jeneker S, Lawn S, Wood R, Bekker LG. Incentivized recruitment of a population sample to a mobile HIV testing service increases the yield of newly diagnosed cases, including those in need of antiretroviral therapy. HIV Med. 2012;13(2):132–7.
Nglazi MD, van Schaik N, Kranzer K, Lawn SD, Wood R, Bekker LG. An incentivized HIV counseling and testing program targeting hard-to-reach unemployed men in Cape Town, South Africa. J Acquir Immune Defic Syndr. 2012;59(3):e28–34.
Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235–42.
Macphail CL, Sayles JN, Cunningham W, Newman PA. Perceptions of sexual risk compensation following posttrial HIV vaccine uptake among young South Africans. Qual Health Res. 2012;22(5):668–78.
Lee SJ, Newman PA, Comulada WS, Cunningham WE, Duan N. Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS. 2012;23(4):235–41.